Immix Biopharma, Inc. (IMMX)
| Market Cap | 997.26M +1,664.6% |
| Revenue (ttm) | n/a |
| Net Income | -39.92M |
| EPS | -0.83 |
| Shares Out | 71.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,143,437 |
| Open | 14.06 |
| Previous Close | 14.31 |
| Day's Range | 13.76 - 14.17 |
| 52-Week Range | 1.94 - 15.10 |
| Beta | 0.11 |
| Analysts | Strong Buy |
| Price Target | 20.27 (+45.41%) |
| Earnings Date | Aug 7, 2026 |
About IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for IMMX stock is "Strong Buy." The 12-month stock price target is $20.27, which is an increase of 45.41% from the latest price.
News
Immix Biopharma price target lowered to $19 from $20 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Immix Biopharma (IMMX) to $19 from $20 and keeps an Overweight rating on the shares. The firm updated its model to reflect…
Immix Biopharma Slides: Corporate presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Immix Biopharma price target raised to $25 from $20 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Immix Biopharma (IMMX) to $25 from $20 and keeps a Buy rating on the shares. post the Q2 report.
Immix Biopharma Quarterly report: Q2 2026
Immix Biopharma has published its Q2 2026 quarterly earnings report on August 7, 2026.
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $IMMX--IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law.
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that ...
Immix Biopharma initiated with a Buy at Needham
Needham initiated coverage of Immix Biopharma (IMMX) with a Buy rating and $21 price target Immix’s lead agent, NXC-201, has shown “compelling” early efficacy and safety, says the analyst, who…
Immix Biopharma Investigated by the Portnoy Law Firm
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma , (“ Immix " or the "Company") ( NASDAQ : IMMX) investors that the firm has initiated an investigation into...
Immix Biopharma announces termination of CMO Richard Graydon
In a regulatory filing, Immix Biopharma (IMMX) announced that as of July 17, Richard Graydon has been terminated and is no longer with the company for reasons unrelated to his…
Wanted fugitive secretly working at Immix as CMO, STAT reports
A fugitive former doctor convicted of sexual assault was arrested after allegedly living under an alias as a biotech executive, including serving as chief medical officer at Immix Biopharma (IMMX)…
Immix Biopharma Slides: Corporate presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on July 3, 2026.
Immix Biopharma initiated with a Buy at BofA
BofA initiated coverage of Immix Biopharma (IMMX) with a Buy rating and $27 price target Early data on NXC-201 shows about 95% complete response and rapid minimal residual disease in…
Immix Biopharma initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Immix Biopharma (IMMX) with an Outperform rating and $19 price target
Immix Biopharma Slides: Corporate presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” ...
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Immix Biopharma (IMMX) to $20 from $15 and keeps a Buy rating on the shares. The company announced that…
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten r...
Immix Biopharma’s NXC-201 reaches 95% complete response rate in AL amyloidosis
Immix Biopharma (IMMX) announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response – CR -. The NEXICART-2 CR rate is now…
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-d...
Immix Biopharma Quarterly report: Q1 2026
Immix Biopharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
Immix Biopharma Slides: Corporate presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on April 30, 2026.
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that...
Immix Biopharma Proxy statement: Proxy filing
Immix Biopharma filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Immix Biopharma Proxy statement: Proxy filing
Immix Biopharma filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3, followed by BLA submission and planned commercial launch. In add...